Differences

This shows you the differences between two versions of the page.

Link to this comparison view

start [2017/06/06 14:45]
f.demichelis@unitn.it
start [2017/06/06 15:46] (current)
f.demichelis@unitn.it
Line 4: Line 4:
  
 The laboratory integrates computational and experimental work and is characterized by inter-disciplinary/inter-institutional collaborations that allow for a challenging and stimulating atmosphere and state-of-the-art approaches. The laboratory integrates computational and experimental work and is characterized by inter-disciplinary/inter-institutional collaborations that allow for a challenging and stimulating atmosphere and state-of-the-art approaches.
 +
 +Follow us on {{:twitter.png?30|[[https://twitter.com/FrancescaBZNY]]}}
  
 <html>  <html> 
Line 12: Line 14:
  
  
-**June 5th 2017**: **ASCO 2017** Whole exome sequencing of circulating tumor DNA (ctDNA) in patients with neuroendocrine prostate cancer presented at ASCO 2017 was featured in UroToday. ([[https://www.urotoday.com/conference-highlights/asco-2017/asco-2017-prostate-cancer/96283-asco-2017-whole-exome-sequencing-of-circulating-tumor-dna-ctdna-in-patients-with-neuroendocrine-prostate-cancer-informs-tumor-heterogeneity.html|article]]).+**June 5th 2017**: **ASCO 2017** Whole exome sequencing of circulating tumor DNA (ctDNA) in patients with neuroendocrine prostate cancer presented at ASCO 2017 was featured in UroToday. Collaboration with Weill Cornell Medicine.([[https://www.urotoday.com/conference-highlights/asco-2017/asco-2017-prostate-cancer/96283-asco-2017-whole-exome-sequencing-of-circulating-tumor-dna-ctdna-in-patients-with-neuroendocrine-prostate-cancer-informs-tumor-heterogeneity.html|article]]).
  
 ---- ----